Chest disease
Conditions
Interventions
Experimental group:Individualized anticoagulation strategy based on the new VTE risk assessment system
Control group:Conventional anticoagulation strategy
Sponsors
Beijing Chao-Yang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The target population is patients with perioperative thoracic disease in multicenter thoracic surgery from November 2024 to December 2026
Exclusion criteria
Exclusion criteria: 1. Pregnancy, breastfeeding; 2. Active bleeding or serious risk of bleeding; 3. Suffering from severe liver disease; 4. Severe renal insufficiency (CCR<30ml/min); 5. Contraindications to the use of natraheparin; 6. Use other anticoagulant therapy; 7. Discontinuation of anticoagulant therapy; 8. Patients with secondary malignant tumors of the lungs; 9. Patients with VTE confirmed by preoperative imaging; 10. Patients with missing information or lost to follow-up, especially those who do not have relevant imaging tests (lower extremity venous ultrasound or CTPA) after surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Biomarkers;Complete blood count;Coagulation-related markers;Inflammatory indicators;Imaging tests; | — |
Countries
China
Contacts
Public ContactMiao Jinbai
Beijing Chao-Yang Hospital, Capital Medical University
Outcome results
None listed